PRENATAL METHAMPHETAMINE EXPOSURE AND CHILD DEVELOPMENT (IDEAL)

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 我们已经建立了一个社区研究网络（CRN），进行纵向研究或产前甲基苯丙胺（MA）的暴露和儿童的结果在四个地区，其中MA使用是普遍的。 数据收集地点包括9家医院，合并年分娩率约为27，300名新生儿。将通过母体自我报告和/或GC/MS确认胎粪筛查阳性来确定暴露状态。我们预计，在所有地点，产前MA暴露的平均患病率为4%。样本将包括MA暴露组中的254例受试者和对照组中的254例受试者，这些受试者在其他药物使用、早产、社会阶层、性别和种族方面匹配。该样本量提供了足够的把握度来检测适当协变量的控制的小的统计效应。 2002年9月4日开始入组。我们的计划是进行一项为期3年的纵向研究，其中1年用于筛选和招募样本，并在新生儿期、1年、2年和3年进行发育随访，并在18个月时进行家访。对儿童的测量包括唤醒调节、认知、社会关系、神经运动、神经内分泌功能和医疗状况的领域。心理社会风险因素的措施包括养育环境和照顾者的特点。我们将检验与产前MA暴露对儿童结局影响相关的假设，当控制协变量（包括其他药物使用）时，以及与心理社会风险因素介导产前MA暴露对儿童结局影响相关的假设。这项研究将使我们能够承担的经验和进步的方法和教训，从研究产前暴露于其他药物的产前MA暴露的研究，以及研究和临床专业知识与MA。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We have established a Community Research Network (CRN), to conduct a longitudinal study or prenatal methamphetamine (MA) exposure and child outcome in four areas in which MA use is prevalent. The data collection sites include 9 hospitals with a combined annual delivery rate or approximately 27,300 newborn infants. Exposure status will be determined by maternal self-report and/or GC/MS confirmation of a positive meconium screen. We are projecting an average 4% prevalence rate of prenatal MA exposure across the sites. The sample will include 254 subjects in the MA exposed group and 254 subjects in the comparison group matched for other drug use, prematurity, social class, gender and race. This sample size provides sufficient power to detect small statistical effects with controls for appropriate covariates. Enrollment started 9/4/2002. Our plan is to conduct a three-year longitudinal study with 1 year to screen and recruit the sample and developmental follow-up in the newborn period, 1, 2, and 3 years and a home visit at 18 months. Measures of the child include domains of arousal regulation, cognition, social relationships, neuromotor, neuroendocrine function, and medical status. Measures of psychosocial risk factors include caregiving context and caregiver characteristics. We will test hypotheses related to the effects of prenatal MA exposure on the child outcome when covariates including other drug use are controlled and hypotheses related to the role of psychosocial risk factors mediating effects of prenatal MA exposure on child outcome. This study will enable us to bring to bear experiences and advances in methods and lessons learned from the study of prenatal exposure to other drugs to the study of prenatal MA exposure, as well as research and clinical expertise with MA.